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Abstract
Background: Expression of the microRNA miR-21 has been found to be altered in almost all types of cancers and it
has been classified as an oncogenic microRNA or oncomir. Due to the critical functions of its target proteins in
various signaling pathways, miR-21 is an attractive target for genetic and pharmacological modulation in various
cancers. Cervical cancer is the second most common cause of death from cancer in women worldwide and
persistent HPV infection is the main etiologic agent. This malignancy merits special attention for the development
of new treatment strategies. In the present study we analyze the role of miR-21 in cervical cancer cells.
Methods: To identify the downstream cellular target genes of upstream miR-21, we silenced endogenous miR-21
expression in a cervical intraepithelial neoplasia-derived cell lines using siRNAs. The effect of miR-21 on gene
expression was assessed in cervical cancer cells transfected with the siRNA expression plasmid pSIMIR21. We
identified the tumor suppressor gene PTEN as a target of miR-21 and determined the mechanism of its regulation
throughout reporter construct plasmids. Using this model, we analyzed the expression of miR-21 and PTEN as well
as functional effects such as autophagy and apoptosis induction.
Results: In SiHa cells, there was an inverse correlation between miR-21 expression and PTEN mRNA level as well
as PTEN protein expression in cervical cancer cells. Transfection with the pSIMIR21 plasmid increased luciferase
reporter activity in construct plasmids containing the PTEN-3′-UTR microRNA response elements MRE21-1 and
MRE21-2. The role of miR-21 in cell proliferation was also analyzed in SiHa and HeLa cells transfected with the
pSIMIR21 plasmid, and tumor cells exhibited markedly reduced cell proliferation along with autophagy and
apoptosis induction.
Conclusions: We conclude that miR-21 post-transcriptionally down-regulates the expression of PTEN to promote
cell proliferation and cervical cancer cell survival. Therefore, it may be a potential therapeutic target in gene therapy
for cervical cancer.
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Background
MicroRNAs are a recently discovered family of genes en-
coding small RNA molecules of 19–25 nucleotides in
length which bind through partial sequence homology to
the 3′-untranslated regions (3′-UTRs) of mRNA from
cell target genes, induce repression of translation and, as
a result, play key roles in the regulation of gene expres-
sion and of the dynamics of development in a great var-
iety of eukaryotic organisms [1]. Homo sapiens miR-21
(hsa-miR-21) is one of first microRNAs detected in the
human genome and to date is the major oncomir known
to be up-regulated in all types of human cancer includ-
ing glioblastoma multiforme [2], breast [3], lung [4],
esophageal [5], gastrointestinal [6], hepatocellular [7],
cholangiocarcinoma [8], pancreatic [9], prostate [10],
bladder [11], ovarian [12], NK-cell lymphoma [13],
laryngeal carcinoma [14] and tongue squamous cell
carcinoma [15]. Therefore, much research has been con-
ducted to determine its physiological and pathophysiolo-
gycal functions during embryonic development and cell
proliferation, differentiation and death [16–19]. Recently,
an integral role for miR-21 in tumor pathogenesis has
emerged, with extensive studies indicating that miR-21
is involved in all known cancer-related processes
including tumorigenesis, progression and metastasis
[19–22]. Furthermore, the level of miR-21 expression is
significantly associated with clinical-pathological factors
and the prognosis of cancer patients, suggesting that it
could be utilized as a diagnostic and prognostic marker
in human malignancy [23–28].
Currently, there are few microRNAs whose physiologic
function has been elucidated in vivo and whose gene tar-
gets are known. Among these is miR-21, located at
chromosome 17q23.2 locus, which codes for pri-miR-21
located within the intronic region of the protein-coding
gene TMEM49 [25]. Inhibition of miR-21 can induce cell
cycle arrest and increase chemosensitivity to anticancer
agents, providing evidence that miR-21 may function as
an oncogene in various human cancers [5, 7, 9, 19, 27].
Recently, several significant miR-21 targets associated
with malignancy have been identified by different
groups: Phosphatase and tensin homologue deleted on
chromosome ten (PTEN) [28], programmed cell death 4
protein (PDCD4) [29], reversion-inducing-cysteine-rich
protein with kazal motifs (RECK) [19], maspin [30],
tropomyosin 1 (TPM1) [31], heterogeneous nuclear ribo-
nucleoprotein K (HNRPK) and TAp63 [27]. In addition,
previous studies have reported that miR-21 expression
levels are significantly higher in tumor cervical sam-
ples compared with their normal tissue counterparts
[32–34]. However, the functional activity of miR-21 in
cervical cancer cells remains largely unknown, and
thus far, few miR-21 gene targets in cervical cells
have been reported.
Cervical cancer is the second most common malig-
nancy affecting women worldwide, with approximately
500,000 new cases diagnosed and 280,000 deaths occur-
ring each year. The highest incidences occur in the de-
veloping world, where, in most countries, cervical cancer
is the leading cause of cancer mortality in women [35].
Although the relationship between persistent high-risk
HPV infection and cervical cancer development has
been well documented in clinical, epidemiological, mo-
lecular and functional studies [36], the detailed regula-
tory network of events leading from HPV infection to
tumor development has yet to be elucidated. An event
that occurs in HPV-associated carcinogenesis during
HPV DNA integration is a global perturbation of cellular
gene expression, mainly by the HPV E6 and E7 onco-
gene expression [37–39]. Recent evidence suggests a re-
lationship between HPV E6 and E7 oncogene expression
and disruption of cellular microRNA expression. Many
cellular transcription factors, including AP-1, c-Myc,
E2F, NF-kB, pRb, and p53, have been determined to
regulate the transcription of microRNAs [40]. There-
fore, it is plausible that HPV infection causes aberrant
cellular gene expression including disruption of micro-
RNA expression.
In the present study, SiHa and HeLa cells, which are
human cervical cancer cells infected with HPV16 and
HPV18, respectively, were used as a cervical cancer
model to investigate whether siRNA-mediated gene si-
lencing specific to miR-21 expressed in plasmids, could
be used to silence miR-21. We determined whether
these siRNAs could alter the expression of the tumor
suppressor gene PTEN, which has been reported as a
miR-21 target gene in other malignancies. In addition,
we evaluated the biological effects of siRNAs targeting
miR-21 in tumor cells. To this end, we generated siRNA
expression plasmids for miR-21, which have nucleotide
complementarity to the gene coding for pre-miR-21. We
found that these siRNAs could induce silencing of miR-
21. Furthermore, we found that siRNAs against miR-21
induced the reestablishment of PTEN gene and protein
expression, as well as reestablishment of its biological ef-
fects on cell proliferation. Our results indicate that SiHa
and HeLa cell death occurred by autophagy and apop-
tosis, the latter through caspase-3/7 activity, in response
to the silencing of miR-21. To describe the molecular
mechanism of PTEN gene regulation by miR-21 and test
its potential trans-regulatory abilities, we investigated
the effect of miR-21 on the PTEN 3′-UTR regulatory re-
gion in cervical tumor cells. We found that miR-21 can
trans-regulate the PTEN 3′-UTR regulatory region. This
effect is the result of miR-21’s interaction with a specific
MRE (microRNA response element) recognition se-
quence located in position 1925 to 1956 nt (denomi-
nated MRE21-2) in the PTEN 3′-UTR. Taken together,
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these findings demonstrate that siRNAs directed against
miR-21 are excellent molecular tools to inhibit this
microRNA’s expression and activities in a targeted man-
ner to induce reestablishment of target cell gene expres-
sion, which has relevant biological effects on tumor cell
progression.
Methods
Cell lines and culture conditions
Human cervical cancer cells transformed with HPV16
(SiHa cells), and HPV18 (HeLa cells) were obtained
from the American Type Culture Collection (ATCC).
The cell line was cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen, Carlsbad, CA) supple-
mented with 10 % fetal bovine serum (FBS), penicillin/
streptomycin (50 μg/ml), 2 mM L-glutamine, 250 ng/ml
fungizone, and maintained at 37 °C in 5 % CO2. The
total RNA isolation was carried out with TriPure isola-
tion reagent (Roche, Indianapolis, IN) for the end-point
RT-PCR and real time RT-qPCR assays. The cellular
protein isolation was performed and protein concentra-
tion was determined by the BCA protein kit (Pierce,
Rockford, IL.) for the Western Blot assays. The cells
were attached on a slide for epifluorescence microscopy
assays or fixed in ethanol for the flow cytometry assays.
In addition, the cells which were used in transfection as-
says were analyzed for the luciferase activity assays.
siRNA expression plasmids for human microrna miR-21
DNA inserts encoding siRNAs specific for human
microRNA hsa-mir-21 [miRBase: MI0000077] were de-
signed using software from Applied Biosystems-Ambion
[41] and were cloned in Apa I and Eco RI restriction
sites in the pSilencer1.0-U6 siRNA expression plasmid
(Applied Biosystems, Foster, CA), which contains the U6
RNA Pol-III promoter to generate small RNA tran-
scripts, to generate the pSIMIR21 plasmid. The DNA in-
sert was generated using the sense 5′-CAC-CAG-TCG-
ATG-GGC-TGT-CTT-CAA-GAG-AGA-CAG-CCC-AT
C-GAC-TGG-TGT-TTT-TT-3′ and antisense 5′-AAT-T
AA-AAA-ACA-CCA-GTC-GAT-GGG-CTG-TCT-CTC-
TTG-AAG-ACA-GCC-CAT-CGA-CTG-GTG-GGC-C-
3′ primers. The primers were aligned using annealing
buffer (300 mM HEPES pH 7.4, 100 mM potassium
acetate, 2 mM magnesium acetate) at a ratio of 100 mM
and incubated at 95 °C for 5 min and 37 °C for 1 h. To
address the possibility of homologous sequences with
other human genes, the siRNAs-encoding sequences
were analyzed with Blast. The integrity of all plasmid
constructs was verified by DNA sequencing in Gen-
etic Analyser 3500xl equipment (Applied Biosystems,
Foster, CA).
Transfection assays with siRNA expression plasmids
SiHa and HeLa cells were transiently transfected with
pSIMIR21 plasmid to silence miR-21, using Fugene HD
transfection reagent (Promega, Madison, WI) according
to the manufacturer’s instructions. Briefly, one day be-
fore the transfection assay, the cells were plated at a
density of 1X105 cells per well in a six-well plate con-
taining 2 ml of DMEM with 10 % FBS and penicillin/
streptomycin. At the time of transfection, the plasmids
and Fugene reagent were diluted in DMEM and incu-
bated for 20 min at room temperature. The plasmid
DNA concentration and Fugene reagent were normal-
ized by transfection with pGFP plasmid and all assays
were carried out with 0, 3 and 5 μg of plasmids. SiHa
and HeLa cells were incubated with plasmids and
Fugene for 4 h, rinsed and replenished with DMEM con-
taining 10 % FBS. The plasmids were isolated with Pure-
Yield plasmid midiprep system (Promega, Madison, WI)
and integrity was verified by DNA sequencing. After
48 h of transfection the cells were harvested and RNA
isolation was carried out for semiquantitative end-point
RT-PCR as well as for quantitative real-time RT-PCR as-
says. Cellular protein isolation was performed by West-
ern Blot assays. After transfection, cells were used for
epifluorescence microscopy as well as flow cytometry
and evaluation of reporter plasmid activity and caspases-
3/7 activity. Transfection assays were repeated at least
four times independently.
Cellular viability assays
Cellular viability was measured using [3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium] inner salt MTS assay (Promega,
Madison WI), which is a colorimetric method for deter-
mining the number of viable cells in a proliferation or
cytotoxicity assay. Briefly, a total of 2X104 SiHa cells per
well were plated in a 96-well plate. After 24 h of plating,
20 μl of MTS reagent was added into each well contain-
ing the untreated cells and cells transfected with pSI-
MIR21 plasmid in 100 μl DMEM, and these were
incubated at 37 °C for 4 h. MTS tetrazolium compound
salt reagent is bioreduced by living cells into a colored
formazan product that is soluble in tissue culture
medium. After incubation, the absorbance values were
measured at 490 nm in an automatic microplate reader.
Cellular viability rate was calculated as the percentage of
MTS adsorption as follows: % survival = (mean experi-
mental absorbance/mean control absorbance) X 100.
Each assay was carried out three separate times.
Semiquantitative end-point RT-PCR analysis
Transfected SiHa cells were harvested and processed for
total RNA isolation using TriPure isolation reagent
(Roche, Indianapolis, IN) according to the manufacturer’s
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protocol. Briefly, cells were washed with 1X PBS and
1 ml TriPure was added. 200 μl chloroform was
added and the cells were centrifuged. The aqueous
phase was separated and the RNA was precipitated
with isopropanol. The RNA was dissolved in DEPC-
water and the concentration was measured. The mRNA
was obtained using oligo dT dT15-18 (Promega, Madison,
WI) and cDNA synthesis was performed by incubation
with M-MLV reverse transcriptase (Promega, Madison,
WI) at 37 °C during 1 h. Homo sapiens PTEN gene ex-
pression [NCBI: NM_000314] was measured by semi-
quantitative end-point RT-PCR using the sense 5′-GGG-
AAG-ACA-AGT-TCA-TGT-AC-3′ and antisense 5′-
AGT-ATC-GGT-TGG-CTT-TGT-C-3′ primers which
were generated using the GeneFisher2-interactive PCR
primer design software [42]. The PCR reaction amplifica-
tion conditions were 95 °C for 10 min, 95 °C for 1 min,
55 °C for 30 s and 72 °C for 1 min for 35 cycles followed
by 72 °C for 10 min. A 309 bp DNA fragment was ob-
tained for PTEN gene. The glyceraldehyde-3-phosphate
dehydrogenase (GADPH) housekeeping gene was used as
a control using sense 5′-CAA-CAG-CCT-CAA-GAT-
CAT-C-3′ and antisense 5′-ACC-AGG-AAA-TGA-GCT-
TGA-C-3′ primers. The PCR reaction amplification con-
ditions were 95 °C for 10 min, 94 °C for 1 min, 54 °C for
1 min and 72 °C for 1 min for 35 cycles followed by 72 °C
for 10 min. A 520 bp DNA fragment was obtained. For
each PCR reaction, 1 μg cDNA, 2.5 mM dNTPs, 20 pM
each primer and 0.5 U Taq (Promega, Madison WI) were
used in a 25 μl volume reaction. To ensure that amplifica-
tion remained within the linear range, 1:5 serial dilutions
of cDNA were made.
Quantitative real time RT-PCR analysis
Total RNA isolation from SiHa cells transfected as pre-
viously described was carried out with TriPure isolation
reagent (Roche, Indianapolis, IN). The cDNA synthesis
was performed by incubation with 100 ng RNA, 1X RT
buffer, 0.25 mM each dNTPs, 0.25 U/μl RNase-OUT in-
hibitor and 3.33 U/μl M-MLV reverse transcriptase, in a
one step 7.5 μl volume reaction. The reaction was incu-
bated in a 384 well plate at 37 °C during 30 min in Ap-
plied Biosystems 7900 Real-Time PCR Instrument. For
analysis of miR-21 expression, real time RT-qPCR ana-
lyses were performed using TaqMan pri-miRNA assays
(Applied Biosystems, Foster, CA) according to the man-
ual. Ct values were analyzed to determine the statistical
significance of miR-21 expression in SiHa cells trans-
fected or non-transfected with pSIMIR21 expression
plasmid. Relative expression was calculated using the
2-ΔΔCt method and normalized to the expression of
RNU6 (Applied Biosystems, Foster, CA) [43, 44]. The
reaction was incubated in a 384 well plate in Applied
Biosystems 7900 Real-Time PCR Instrument. All RT-
qPCR were performed in triplicate.
Western blot assays
Forty eight hours after transfection assays, SiHa cells
were harvested and protein was isolated for Western
Blot assays. Briefly, the cells were washed with 1X PBS
and incubated for 30 minites at 4 °C with lysis buffer
containing 50 mM Tris–HCl, 150 mM NaCl, 0.5 % SDS,
1 % NP40, 0.5 mM AEBSF, 10 μg/μl antipain, 10 μg/μl
aprotinin, 10 μg/μl khymostatin, 10 μg/μl leupeptin,
10 μg/μl pepstatin, 1 mM EDTA, 100 mM PMSF and
0.5 mM DTT (Sigma-Aldrich, NJ). The lysates were cen-
trifuged at 11,000 rpm for 15 min. Total proteins from
supernatants were determined using the BCA kit (Pierce,
Rockford, IL). 50 μg of proteins were electrophoresed on
12 % SDS-PAGE, transferred into nitrocellulose mem-
branes and incubated for antibodies detection. Biotinilated
and pre-stained molecular weight marker was included.
IgG mouse monoclonal antibody sc-7974-HRP was used to
detect human PTEN protein. Human beta-actin protein
was detected using IgG polyclonal antibody sc-1616-HRP
(Santa Cruz, Biotechnology, Santa Cruz, CA). After the per-
oxidase coupled secondary goat antibody mouse anti-IgG
was added, bound antibodies and protein were detected by
enhanced chemiluminescence using the renaissance West-
ern Blot kit (Pierce, Rockford, IL). The membranes were
subjected to autoradiography with an intensifier screen.
Reporter plasmids and luciferase activity assays
SiHa cells were transiently transfected with pMRE21P-
tenLuc1 and pMRE21PtenLuc2 reporter plasmids, which
contain cloned the MRE21-1 (microRNA response ele-
ments for miR-21 of 1628 to 1649 nt) and MRE21-2 (of
1925 to 1955 nt) of PTEN-3′-UTR regulatory region.
The information was generated from nucleotide se-
quence database for PTEN [GeneBank: NM_000314.4]
and for hsa-miR-21 [GeneBank: MI0000077]. The
MRE21-1 and MRE21-2 were cloned in Spe I and Hind
III restriction sites of pMIR-Report-Luciferase reporter
vector (Life Technologies, NY), which contains a firefly
luciferase reporter gene under the control of a CMV
promoter/termination system. The design of construct
plasmids was carried out in target scan human predic-
tion of microRNA targets software [45]. The co-
transfection assays were performed with pSIMIR21
plasmid which expresses siRNAs for miR-21. The
pMRE21PtenLuc1 plasmid was generated for cloning of
PCR product of 387 bp DNA fragment using the sense 5′-
GAC-TGA-TCA-CTT-TCC-CGT-TTT-ATT-CC-3′ and
antisense 5′-CCC-AAG-CTT-AAT-GCG-CAA-ACA-AC
A-AGC-3′ primers. The pMRE21PtenLuc2 plasmid was
generated for cloning of PCR product of 364 bp DNA
fragment using the sense 5′-GAC-TAG-TTT-GGC-TAA-
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GAG-AGG-TTT-CC-3′ and antisense 5′-CCC-AAG-C
TT-TTG-TTG-CTG-TGT-TTC-TTA-CC-3′ primers. The
plasmids were isolated by PureYield plasmid midiprep sys-
tem (Promega, Madison, WI) and the integrity was veri-
fied by DNA sequencing. SiHa cells were transfected
using Fugene reagent (Promega, Madison, WI) according
to the manufacturer’s instructions as mentioned above.
The beta-galactosidase activity was not affected by
pMRE21PtenLuc plasmids in SiHa cells, therefore the lu-
ciferase activity in all assays were normalized using the
pMIR-Report-Luciferase empty vector and pMIR-Report-
beta-gal reporter plasmids. All transfection assays were
performed with 5 μg of plasmid DNA. SiHa cells were in-
cubated with Fugene reagent for 4 h and 48 h after trans-
fection, cells were washed with 1X PBS and were
harvested and lysed with 100 ml cold lysis buffer (20 mM
Tris–HCl pH 7.4, 10 mM NaCl, 10 mM KCl, 3 mM
MgCl2, 0.5 % Triton X-100. 0.5 % Nonidet P40). The cel-
lular extracts were collected by centrifugation. 50 μg of
total proteins were used to determine luciferase activity.
Luciferase activity was measured and normalized using
the Dual-Glo luciferase assay system (Promega, Madison
WI) in Glomax Multidetection equipment according to
the manufacturer’s instructions. The luminescence was
calculated to normalize results with respect to pMIR-
Report-Luciferase empty vector and the efficiency of
transfection. All transfections and co-transfections were
repeated at least three times independently.
Flow cytometry assays
Transfected SiHa cells were harvested, centrifuged, fixed
in cold 70 % ethanol and stored at −20 °C. Prior to ana-
lysis, the ethanol was removed and cells were incubated at
room temperature for 10 min in 1 ml buffer A (1 mg/ml
citric acid, 0.1 % Nonidet P40, 1.16 mg/ml spermine tetra-
hydrochloride, 60.5 μg/ml trizma hydrochloride pH 7.6)
containing 30 μg/ml porcine pancreatic trypsin. Next, the
SiHa cells were incubated at room temperature for 10 min
with 1 ml of 30 μg/ml trypsinogen and 100 μg/ml ribo-
nuclease A dissolved in buffer A. Then, SiHa cells were in-
cubated at 4 °C for 10 min in 1 ml of 500 μg/ml
propidium iodide and 1.16 mg/ml spermine tetrahydro-
chloride dissolved in buffer A. During each incubation,
cells were vortexed intermittently every 2 min. Approxi-
mately 10,000 nuclei were processed in FACS Sort Becton
Dickinson (Ar laser, 488 nm and 620 nm excitation and
emission wavelengths, respectively) and results were ana-
lyzed with ModFit LT (Verity) software. Instrument set-
tings were fixed using non-transfected SiHa cells.
Epifluorescence microscopy with acridine orange (AO)
and propidium iodide (PI) staining
This technique is based on a double staining of the cell
and observation of the nucleus. AO is permeable into all
cells while PI only permeates cells where membrane is
compromised. The state of the nucleus is then analyzed.
In the case of programmed cell death, specifically apop-
tosis, the cell nucleus is fragmented and is observed as
green in the early apoptosis phase and red in the late
apoptosis phase. During necrosis and cell death, the nu-
cleus is stained red but the morphology is similar to the
viable cells (stained green). Attached samples of SiHa
and HeLa cells on a slide were harvested at 48 h after
transfection and stained with 5 μg/ml of each dye.
Apoptosis control was induced by 5 μM of H2O2 added
to cell culture during 2 h. A Nikon Elipse 400 epifluores-
cence microscope was used and samples were analyzed
by FITC/TRITC using the 20X or 40X Fluor objectives.
Caspase-Glo-3/7 assays
The caspase-Glo-3/7 assay is a homogenous, lumines-
cent assay that measures caspase-3 and caspase-7 activ-
ities. Briefly, a total of 2X104 cells per well were plated
in a 96-well plate. Caspase-Glo-3/7 reagent (Promega,
Madison WI) containing 100 μl of blank reaction, nega-
tive control cells and treated cells in culture medium
was added to each well of a white-walled 96-well plate.
The blank reaction was used to measure background lu-
minescence associated with the cell culture system and
caspase-Glo-3/7 reagent. The plate was covered with the
lid and gently mixed at 300 rpm for 30 s. The plate was
incubated at room temperature for 1 h. After incubation,
the luciferase activity was measured and normalized
using the Dual-Glo luciferase assay system (Promega,
Madison WI) in Glomax Multidetection equipment ac-
cording to the manufacturer’s instructions. Cell apop-
tosis rate was calculated as the subtracted value for the
blank reaction from experimental values X 100. The lu-
minescence value corresponds to relative light units.
Each assay was carried out three separate times.
Statistical analysis
All experiments were performed at least three times.
The data were analyzed and X2 test was carried out to
compare frequencies between the different experimental
groups. P-values less than 0.01 were considered to be statis-
tically significant and were indicated with an asterisk (*).
Results
siRNA expression plasmids for miR-21 induce silencing of
human microRNA miR-21
The effect of siRNAs on miR-21 can be influenced by
secondary structure and positioning of the cognate se-
quence within the pre-miR-21 molecule. To analyze the
effect of the pSIMIR21 plasmid, we first determined
whether siRNAs could induce specific silencing of miR-
21 expression after transient transfection of pSIMIR21
plasmid. For this purpose, SiHa cells were transiently
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transfected with the pSIMIR21 plasmid and we analyzed
the miR-21 expression level by real time RT-qPCR. As
shown in Fig. 1, there was a significant decrease in the
miR-21 transcript level when cells were transfected with
pSIMIR21 plasmid at higher concentrations. After 48 h
of transfection, the miR-21 expression level decreased by
70 % compared with cells transfected with pSilencer1.0-
U6 plasmid (empty vector). We did not observe differ-
ences in miR-21 expression levels between SiHa cells
treated with pSilencer1.0-U6 compared with non-
transfected SiHa cells. The RNU6 RNA expression level
did not show any changes under these same conditions.
These data suggest that pSIMIR21 is a siRNA expression
plasmid specific for miR-21, which has the ability to
induce selective and specific silencing of miR-21 micro-
RNA in human cervical cancer cells infected with
HPV16.
siRNA-mediated silencing of miR-21 expression has an
effect on PTEN expression
In exploring miR-21 target genes, we focused on phos-
phatase and tensin homolog deleted on chromosome 10
(PTEN), a tumor suppressor gene whose protein product
is involved in the removal of phosphate groups from key
intracellular phosphoinositide 3-kinase signaling mole-
cules. To achieve this aim, SiHa cells were transiently
transfected with the pSIMIR21 siRNA expression
plasmid to induce the silencing of miR-21, which is over
expressed in this type of cells. With the goal of
evaluating whether the PTEN gene is a cellular target of
miR-21 in cervical cancer, we analyzed PTEN gene ex-
pression in SiHa cells transfected with pSIMIR21 plas-
mid, using end-point RT-PCR. As shown in Fig. 2, we
found that siRNA against miR-21 has an effect on the
expression of PTEN mRNA. Specifically, we found sig-
nificant reestablishment of PTEN mRNA expression
when cells were treated with siRNAs to miR-21 at a
higher concentration. After 48 h of transfection with
pSIMIR21, the PTEN expression level increased by more
than 60 % compared with cells transfected with pSilen-
cer 1.0-U6 (empty vector) as well as with the negative
control pSilencer 2.0-U6 neo vector, which expresses a
hairpin siRNA with limited homology to any know se-
quence in human genome. We did not observe differ-
ences in PTEN mRNA expression levels between SiHa
cells transfected with pSilencer 1.0-U6 and negative con-
trol pSilencer 2.0-U6 neo vector, compared with un-
treated SiHa cells. The GAPDH mRNA expression level
did not show any changes in similar transfection condi-
tions. These data suggest that silencing of miR-21 micro-
RNA can induce selective and specific reestablishment
of PTEN gene expression in HPV16+ human cervical
cancer cells.
Furthermore, we analyzed whether the silencing effect
of miR-21 alters PTEN protein expression. Using West-
ern Blot assay, we identified the reestablishment of
PTEN cellular protein expression after treatment of SiHa
cells with siRNAs to miR-21 (Fig. 3). We used beta-actin
protein as a control and did not observe any alteration
in beta-actin cellular protein expression when SiHa cells
were transfected with the pSIMIR21 plasmid. Thus, our
results demonstrate that treatment of SiHa cells with
siRNAs expressed in plasmid specific for miR-21 induces
repression of miR-21 and reestablishment of PTEN gene
expression and its protein product. Thus, expression of
miR-21 microRNA is inversely correlated with PTEN ex-
pression, suggesting that PTEN is a miR-21 target gene
in HPV16+ cervical tumor cells.
Specific MRE recognition sequences by miR-21 are critical
for regulation of PTEN
In an effort to demonstrate that miR-21 directly targets
the PTEN gene, two independent luciferase reporter plas-
mids were generated (pMRE21PtenLuc1 and pMRE21P-
tenLuc2), containing cloned microRNA response
elements (MREs) to miR-21 from the PTEN 3′-UTR regu-
latory region (MRE21-1 of 1628 to 1650 nt and MRE21-2
of 1925 to 1956 nt) (Fig. 4a). SiHa cells were transiently
transfected with pMRE21PtenLuc1 and pMRE21PtenLuc2
reporter plasmids independently to determinate the con-
tribution of each MRE21 recognition site, and subse-
quently co-transfected with the pSIMIR21 plasmid to
determine the effect of silencing miR-21. Transfection
Fig. 1 Silencing of human microRNA miR-21 expression by siRNAs.
Quantitative real time RT-PCR analysis of miR-21 expression in SiHa cells
transfected with pSIMIR21 plasmid. Total RNA and cDNA synthesis
were obtained from 1 × 105 SiHa cells (HPV16+) per well in a six-well
plate containing DMEM at 37 °C with 5 % CO2 after 48 h transfection
with pSIMIR21 plasmid (0, 0.5, 1, 3 and 5 μg). Relative expression by
real-time RT-qPCR analysis of miR-21 was calculated using the 2-ΔΔCt
method and was normalized by miR-21/RNU6 ratio relative expression
units. The Ct values were analyzed with pSilencer 1.0-U6 empty vector
transfection and pSIMIR21 plasmid and values are presented as mean
± SD. The P values <0.01 are indicated with asterisks
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with pMRE21PtenLuc1 did not induce luciferase activity
while transfection with pMRE21PtenLuc2 caused an ap-
proximately 60 % decrease in luciferase activity compared
with SiHa cells transfected with pMIR-Report-Luciferase
plasmid (empty vector). When SiHa cells were co-
transfected with pSIMIR21 and pMRE21PtenLuc1 plas-
mids, the luciferase activity was very similar to control
non-transfected SiHa cells. Interestingly, when SiHa cells
were co-transfected with pSIMIR21 and pMRE21Pten-
Luc2 plasmids, luciferase activity increased twofold in
comparison with transfection with pMIR-Report-
Luciferase empty vector (Fig. 4b). These data suggest that
MRE21-2 sequence is the main recognition site through
which miR-21 mediates regulation of the PTEN gene.
MRE21-2 is located from 1925 to 1956 nt downstream of
the transcriptional start site of PTEN gene and appears
particularly important for miR-21’s targeting mechanism
of PTEN gene, given that MRE21-2 induced greater regu-
lation of luciferase reporter gene. However, further investi-
gation is needed to elucidate the specific molecular
mechanism by which miR-21 interacts with MREs on the
PTEN gene. These findings do suggest that a possible
mechanism by which miR-21 regulates the PTEN gene in
human cervical tumor cells is through interaction with the
MRE21 recognition sites, principally MRE21-2.
miR-21 silencing induces autophagy and apoptosis of
cervical cancer cells
To determine whether silencing of miR-21 expression by
siRNAs affects cellular viability, MTS assays were
carried-out on days 0, 1, 2, 3, 4 and 5 after transfection;
using equal amounts of SiHa cells transfected with pSI-
MIR21 plasmid. Silencing of miR-21 decreased the via-
bility of SiHa cells compared with cells transfected with
pSilencer 1.0-U6 empty vector (Fig. 5a, b). A marked de-
crease in cellular viability was observed from days 2 to 5
after treatment with siRNAs to miR-21.
The staining with acridine orange of SiHa cells (Fig. 5c)
and HeLa non-treatment control cells showed predom-
inantly green fluorescence with minimal red fluores-
cence in cytoplasmic and nuclear components (Fig. 6).
The cells transfected with pSilencer 1.0-U6 empty vector
showed red fluorescence, and cells in which miR-21 was
silenced displayed considerable red fluorescence, sug-
gesting the formation of numerous acidic autophagoly-
sosomal vacuoles and induction of early apoptosis. As
seen in Fig. 6a, 48 h post-treatment with pSIMIR21,
SiHa cells presented a typical morphology of early apop-
totic cells with fragmented nucleus and compromised
nuclear membrane, similar to the positive control of
apoptosis in treatment with H2O2. This effect was not
Fig. 2 Analysis of PTEN gene expression by semiquantitative end-point RT-PCR after miR-21 silencing. Total RNA and cDNA synthesis were
obtained from 1 × 105 SiHa cells (HPV16+) per well in a six-well plate containing DMEM at 37 °C with 5 % CO2 after 48 h transfection with
pSIMIR21 plasmid. Panel a Analysis of PTEN gene expression by semiquantitative end-point RT-PCR in SiHa cells non transfected (NT, lane 1) or
transfected with pSilencer1.0-U6 plasmid or pSilencer2.0-U6 plasmid (empty vectors) or with pSIMIR21 plasmid (lanes 2 to 4). HaCat cell line was
used as positive control (H, lane 5). PCR reaction without cDNA corresponds to reaction negative control (C-, lane 6). PCR amplification products
were separated by electrophoresis in 1 % agarose gel. The DNA 100 bp ladder was used as molecular weight. Panel b PCR product bands were
digitalized and analyzed by densitometer and data were analyzed by mRNA PTEN/mRNA GADPH ratio in relative expression units
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observed in non-transfected control cells or cells trans-
fected with empty vector. In HeLa cells 48 h post-
treatment with pSIMIR21, the quantity of cells was
lower compared to SiHa cells, suggesting that these cells
were more sensitive to the treatment with silencing of
miR-21 (Fig. 6b). In fact, HeLa cells presented a typical
morphology of early apoptotic cells with fragmented nu-
clei but necrosis was also observed. The experimental
cells differ from the positive apoptosis control treated
with H2O2 in that compromise of the nuclear membrane
and chromatin condensation were observed. Control un-
treated cells and cells transfected with pSilencer 1.0-U6
empty vector were not affected and showed a viable
morphology.
The ideal therapeutic agent in cancer treatment would
selectively induce death of tumor cells without affecting
surrounding normal cells. However, the biological effect
of silencing miR-21 in cervical cancer cells is not well
understood. Therefore, we analyzed the effect of silen-
cing miR-21 gene expression, using siRNAs against miR-
21, on survival of SiHa cells. Analysis of cellular DNA
content by flow cytometry at different phases of the cell
cycle is an effective method to determine whether cells
are proliferating or going through cell death by the
process of apoptosis. We assessed DNA content using
flow cytometry analysis in SiHa cells transiently
transfected with the pSIMIR21 plasmid. After 48 h of
transfection, cell death by apoptosis occurred in 53 to
61 % in SiHa cells transfected with the pSIMIR21 plas-
mid, while 3 to 6 % of SiHa cells underwent cell death
when they were not-transfected or transfected with the
pSilencer 1.0-U6 empty vector (Fig. 7). These findings
suggest that induction of cell death by autophagy and
apoptosis in human cervical cells transfected with pSI-
MIR21, which produces specific siRNAs toward miR-21,
is mediated by silencing of this microRNA’s expression
and is selective to cancer cells transformed with HPV16
and HPV18.
Caspase activation in response to miR-21 silencing
The activity of caspases 3 and 7 can be measured by the
caspase-Glo-3/7 assay. Their activity generates a lumino-
genic caspase-3/7 substrate, which contains the tetrapep-
tide sequence DEVD-AMC, in a reagent optimized for
caspase activity, luciferase activity and cell lysis. The
addition of a single caspase-Glo-3/7 reagent in an add-
mix-measure format results in cell lysis, followed by
caspase cleavage of the substrate and generation of a
glow-type luminescent signal, produced by luciferase.
Luminescence is proportional to the amount of caspase
activity present. In assays carried out in parallel, the ac-
tivity of caspase-3 and caspase-7 were determined
Fig. 3 Analysis of PTEN protein expression by western blot after miR-21 silencing. Total cellular proteins were obtained from 1 × 105 SiHa cells
(HPV16+) per well in a six-well plate containing DMEM at 37 °C with 5 % CO2 after 48 h of transfection with pSilencer1.0-U6 plasmid or pSIMIR21
plasmid (lane 1 cells non transfected NT, lanes 2 and 3 cells transfected with the plasmids, lane 4 (H) corresponds to HaCat cells). The proteins were
separated in 12 % SDS-PAGE and were transferred to nitrocellulose membranes which were incubated with each antibody. Panel a corresponds to
transfection with pSilencer1.0-U6 plasmid. Panel b corresponds to transfection with pSIMIR21 plasmid and subsequent detection of PTEN protein.
Amount similar proteins were analyzed in the immunoblots. The anti-beta-actin antibody was included as control
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together because caspase-3 and −7 utilizes the same sub-
strate DEVD-AMC; therefore, the activity determined by
cleavage of DEVD-AMC is in fact contributed by both
of these caspases. In Fig. 8 we demonstrate that silencing
of miR-21 in SiHa and HeLa cells induced a significant
increase in activity of caspase-3/7 compared with cells
transfected with pSilencer 1.0-U6 empty vector. Cells
treated with H2O2 were used as positive apoptotic con-
trols. We did not observe significant differences in
caspase-3/7 activity levels between untreated SiHa cells
and DMEM media alone. Therefore, these data suggest
that silencing miR-21 has implications on the apoptosis
pathway mediated by caspase-3/7 and results in induc-
tion of early apoptosis in cervical cancer cells.
Taken together, these evidences indicate that adminis-
tration of siRNAs expressed in plasmid against miR-21
can induce silencing of miR-21 gene expression and re-
establish PTEN gene and protein expression, confirming
that PTEN is a target gene regulated by miR-21 through
MRE21-2. Thus, miR-21 appears to have biological ef-
fects on human cervical cancer cells transformed by
HPV16 through the regulation of cell death by autoph-
agy and apoptosis.
Discussion
In the present study we demonstrate that in cervical
cancer, the overexpression of miR-21 can contribute to
the carcinogenesis process by altering the expression of
cellular genes involved in checkpoint regulation, includ-
ing PTEN, which inhibits tumor progression. Here we
report that miR-21 post-transcriptionally down-regulates
the expression of PTEN and inhibits cell proliferation
and survival of cervical cancer cells. MiR-21 is the most
abundantly expressed microRNA in cervical cancer cell
lines as well as in tumor samples [32–34]; its overex-
pression in some HPV-associated cervical cancers may
be related to the integration of HPV16 at fragile site
FRA17B [46], the region in which the gene locus of
miR-21 is located. While the genes and downstream
pathways targeted by miR-21 remain in large part to be
elucidated, the tumor suppressor gene PTEN has been
validated as a miR-21 target in hepatocellular cancer [7],
Fig. 4 Functional analysis of MREs recognition sequences of PTEN gene by miR-21. Panel a. Nucleotide sequences of MRE21-1 and MRE21-2 of
PTEN 3′-UTR regulatory region. MicroRNAs response elements of miR-21 (MRE21-1 of 1628 to 1650 nt and MRE21-2 of 1925 to 1965 nt) and
complementary with miR-21 are indicated. Information was generated from nucleotide sequence database for PTEN [GeneBank: NM_000314.4]
and for hsa-miR-21 [GeneBank: MI0000077]. Panel b. Regulation of PTEN 3′-UTR region modulated by miR-21 microRNA in SiHa cells non transfected
(lane 1) or transfected with pSIMIR21 (lane 2), with pMIR-Report-Luciferase empty vector (lane 3), with pMRE21PtenLuc1 (lane 4), with pMRE21PtenLuc1
and pSIMIR21 (lane 5), with pMRE21PtenLuc2 (lane 6) and pMRE21PtenLuc2 and pSIMIR21 (lane 7) plasmids. After 48 h of transfection, luciferase activity
levels were measured. Data shown represent the average of four independent experiments
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Fig. 6 Epifluorescence staining with Acridine Orange (AO) and Propidium Iodide (PI) in response to miR-21 silencing. SiHa (panel a) and HeLa cells
(panel b) were plated at 70 % confluent on glass coverslips. Attached samples of SiHa and HeLa cells on a slide were harvested at 48 h after
transfection with pSilencer 1.0-U6 or pSIMIR21 plasmids and stained with 5 μg/ml of AO and PI dyes. Apoptosis control was induced by 5 μM of
H2O2 added to cell culture during 2 h. Following transfection, cells were observed in a Nikon Elipse 400 epifluorescence microscopy and samples
were analyzed by FITC/TRITC using the 40X Fluor objective
Fig. 5 Analysis of tumor cell viability for silencing of miR-21 by siRNAs. Panel a SiHa cells were analyzed by white light microscopy (20X) 48 h after
transfection with pSIMIR21 plasmid. The black arrows indicate the dead cells. Panel b Cellular viability was measured using MTS assay kit. Panel c
SiHa cells attached on a slide were harvested at 48 h after transfection and stained with 5 μg/ml of acridine orange and propidium iodide dyes.
Apoptosis control was induced by 5 μM of H2O2 added to cell culture during 2 h. A Nikon Elipse 400 epifluorescence microscope was used and
samples were analyzed by FITC/TRITC using the 20X and 40X Fluor objectives. The white arrows indicate nucleus fragmented
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cholangiocarcinoma [8], non-small cell lung cancer [28]
and recently in cervical cancer [55, 56, 64]. Inhibition of
expression of PTEN can cause cellular transformation
and neoplastic growth by eliminating the “off switch” for
cellular growth and survival signals produced by the
PI3K/Akt pathway [47]. In human gastric cancer, knock-
down of miR-21 increased expression of PTEN and de-
creased tumor cell proliferation, migration and invasion
[48].
We observed that PTEN gene expression and PTEN
cell protein expression were reestablished in HPV16+
human cervical cancer cells when miR-21 expression
was silenced with specific siRNAs expressed in plasmids
(Figs. 2 and 3). A previous study reported the disruption
of miR-21 by genome editing using transcription
activator-like effector nucleases (TALENs) in cancer cells
[49]. In the study, by analyzing single cell-derived miR-
21 knockout clones, it was determined that HeLa cells
(HPV18 positive) lacking miR-21 were phenotypically
less malignantly transformed and more sensitive to cis-
platin. Furthermore, the loss of miR-21 led to a subtle
global increase in mRNAs containing miR-21 target se-
quences. Interestingly, a slight increase in PTEN protein
expression in the miR-21 knockout was observed. These
findings using TALEN-mediated microRNA gene disrup-
tion in HeLa cells are consistent with our data reported
here for SiHa cells (HPV16 positive) using siRNA ex-
pression plasmids, and demonstrate the value of knock-
down using both the techniques of siRNAs and TALEN
in studies of human carcinogenesis. Given that currently
Fig. 8 Detection of caspases activity in response to miR-21 silencing.
SiHa (panel a) and HeLa (panel b) cells were analyzed by caspase-3/7
activities, 48 h after of non-treated (lane NT), treated with H2O2
(apoptosis control), transfected with empty vector (pSilencer 1.0-U6)
and transfected with pSIMIR21 plasmids. DMEM medium alone was
included. Following transfection, luciferase activity levels were
measured and luminescence value corresponded to relative light units.
The values are presented as mean ± SD and P values <0.01 are indicated
with asterisks. Each assay was carried out three separate times
Fig. 7 Apoptosis analysis of cervical cancer cells by silencing of miR-21. SiHa cells were non-transfected or transfected with pSilence1.0-U6
or pSIMIR21 plasmids and were harvested and fixed in 70 % ethanol. Cells were treated with propidium iodide and approximately 100,000 nuclei were
processed by FASC-Sort. The assays were normalized with non-transfected SiHa cells and the data were analyzed with ModFitLT software
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more than 30 miRNAs have been validated to target
PTEN [50], the depletion or silencing of miR-21 may
not on its own explain a drastic decrease in PTEN ex-
pression (Fig. 3). This data suggests that PTEN gene ex-
pression is modulated at the post-transcriptional level by
miR-21, and its regulation is mainly through miR-21’s
interaction with microRNA response elements (MREs)
localized in the 3′-UTR regulatory region of the human
PTEN gene (Fig. 4). This evidence is relevant in the con-
text of reports that PTEN regulates several cellular
checkpoints including the processes of apoptosis [51],
growth, invasion, migration [52] and angiogenesis [53]
through its effects on several signaling pathways. PTEN
functions as a dual specificity phospahatase and its key
target is phosphatidylinositol 3, 4, 5,-triphosphate, the
direct product of the phosphatidylinositol 3-kinase
(PI3K). Thus, the PTEN/PI3K/AKT circuit is a signal
pathway implicated in numerous carcinogenesis-related
processes.
Although multiple mechanisms such as genetic muta-
tion, promoter methylation and post-transcriptional modi-
fication may contribute to deregulation of the PTEN gene,
two microRNA response elements (MRE21-1 and
MRE21-2) have been reported to be involved in PTEN
regulation in several cancers [28, 54]. MREs are binding
sequences in the 3′-UTR of mRNA through which micro-
RNAs suppress their target gene. PTEN MRE sequences
for miR-21 have been reported in the online databases mi-
Randa, Target Scan Human and miRBase, and several
groups have identified and evaluated the putative MRE se-
quences in PTEN’s 3′-UTR. MRE21-1 was identified and
evaluated in lung cancer cells; it corresponds to a 22-
nucleotide sequence from nucleotide 1628 to 1650 in the
PTEN 3′-UTR [28]. While MRE21-2 was identified and
analyzed in glioblastoma cells and corresponds to a 31-
nucleotide sequence from nucleotide 1925 to 1956 in the
PTEN 3′-UTR [54]. Interestingly, we observed that
MRE21-2 was the principal regulatory target of miR-21 in
human cervical cancer cells transformed with HPV16,
which we confirmed by silencing miR-21 (Fig. 4). This
finding suggests that the MREs within the same gene can
induce different responses depending on the biological
context and regulatory genetic networks, which helps to
explain in part why one microRNA can function as an
oncomir in a particular cancer and as a tumor suppressor
gene in a different malignancy.
On the other hand, another study assessed the func-
tional contribution of Let-7a and miR-21, which interact
with STAT3 signaling and/or its downstream effects in
HPV16-positive cervical cancer cells [55]. The specific
targeting of miR-21 using a miR-21 inhibitor resulted in
an increased level of PTEN expression, thus negatively
regulating STAT3. In addition, siRNA-mediated inhib-
ition of HPV E6 oncoprotein resulted in loss of miR-21,
reduction in STAT3 and increase in PTEN. It is likely
that STAT3-induced miR-21 contributes to a relevant
part of positive feedback loop in cervical cancer cells
that keeps several apoptosis-inducing regulators, includ-
ing PTEN, under control, and that miR-21 inhibition re-
lieves PTEN suppression leading to inhibition of STAT3
signaling. In addition, this same group reported clinical
evidence of the existence of a functional loop involving
miR-21 and Let-7a as regulators of STAT3 signaling in
different grades of cervical tissues derived from pre-
cancerous and cancerous lesions (LSIL and HSIL) which
represent the natural history of HPV-induced cervical
carcinogenesis [56]. The data revealed overexpression of
miR-21 in pre-cancer and cervical cancer lesions; the
level increased from LSIL to HSIL. In this study, a high
level of PTEN protein was detected in normal cervical
tissues, while it was diminished in tissues from pre-
cancerous and cancerous lesions.
Taken together, these findings suggest the existence of
a functional circuit involving Let-7a, STAT3, miR-21 and
PTEN in cervical cancer cells. This functional circuit
comprises the regulatory genetic network of miR-21 in a
positive feedback loop through which down-regulation
of PTEN keeps STAT3 activity under control, as re-
ported previously [57]. Our data reported here demon-
strate that miR-21 targets its regulator PTEN, forming a
self-adapting feedback loop and creating a balance
mechanism. This supports the existence of this regula-
tory genetic network in cervical cancer cells. Our data in
cervical cancer cell lines and the evidence in tumor tis-
sues suggest that the miR-21/Let-7a/STAT3/PTEN regu-
latory network may be able to be used as a biomarker in
cervical cancer; however, it is important to be cautious
because its expression can be highly variable within cervical
tissues in different subpopulations. Taken together, these
findings support the notion that microRNAs function co-
operatively with transcription factors in regulating a set of
target genes, allowing coordinated modulation of gene ex-
pression, both transcriptionally and post-transcriptionally.
Thus, our results could contribute to the identification of
more core factors, other parallel regulatory genetic net-
works and relevant motifs in cervical carcinogenesis and/or
other tumorigenesis processes.
The regulatory genetic networks involved in cervical
cancer, including microRNAs, target genes, transcription
factors and host genes, have been increasingly better
characterized [57]. One sub-network centering on PTEN
as its principal component has been described. Accord-
ing to the regulatory genetic network data, miR-21 and
PTEN were found to be differentially expressed in can-
cer cells; together with miR-214, they form an ordered
control system. This regulatory genetic network has a
self-adaptation feedback loop providing a balance mech-
anism for maintenance of cell homeostasis. Thus, the
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circling between miR-21 and PTEN as dominant and
dominating factors simultaneously may explain the bio-
logical effect of inhibition of cell proliferation induced by
silencing miR-21 and reestablishing PTEN expression.
Another relevant regulatory genetic network is medi-
ated by p53. Several microRNAs have been reported to
be involved in the p53 pathway, either being regulated
by p53 or acting directly to suppress the expression of
p53 or its downstream effectors, suggesting an import-
ant role for microRNAs in the p53 signaling pathway
[58–61]. There is no known miR-21 response element in
the p53 3′-UTR in either human or mouse to date.
However, several studies have reported that miR-21 sup-
presses the expression of multiple genes in the p53 net-
work. Downregulation of miR-21 in glioblastoma cells
leads to increased expression of p53 and activators of
the p53 pathway, including JMY, TOPORS, TP53BPS
and DAXX, leading to cell cycle arrest and apoptosis
[27]. In breast cancer cells, inhibition of miR-21 induces
the expression of several genes regulated by p53 at the
mRNA level, including FAM3C, ACTA2, APAF1, BTC2,
FAS, CDKN1A (p21), and SESN1 [62]. These genes are
required for p53 function, suggesting that miR-21 over-
expression may impair the tumor-suppressive function
of the p53 pathway. A recent study reports that miR-21
expression is elevated in human lung tumors with mu-
tated p53 and distant metastases, and that increased ex-
pression of miR-21 confers increased invasiveness in
Trp53-deficient mouse tumors [63]. However, the func-
tional interaction between p53 and miR-21 in vivo has
remained elusive. Given the existing evidence, it is cer-
tainly conceivable that miR-21 regulates the expression
of multiple cellular genes through PTEN, p53 and asso-
ciated regulatory genetic networks, which act as check-
points to maintain cell homeostasis. The miR-21-PTEN
ordered control system has a critical and more complex
function than originally thought, representing a regula-
tory genetic network highly involved in the processes of
carcinogenesis.
We also sought to determine whether the silencing of
miR-21 by siRNAs has an effect on cancer cell prolifera-
tion. We found that siRNAs can silence miR-21 gene ex-
pression, causing a decrease in the level of miR-21
mRNA expression in human cervical cancer cells. To
elucidate the mechanism by which the silencing of miR-
21 inhibits the growth of SiHa cells, we performed cell
viability evaluations (Fig. 5) and induction of cellular
death (Figs. 6 and 7). We observed inhibition of SiHa
cell proliferation and induction of autophagy and apop-
tosis. In addition, the upregulation of miR-21 in invasive
cervical cancer tissues has been reported, and studies
have confirmed that miR-21 promotes proliferation,
migration and invasion in CaSki (HPV16-positive) or
HeLa cells, by downregulating the expression of tumor-
repressive PTEN [64]. This effect can be explained by the
fact that PTEN inhibits cell migration and invasion by dir-
ectly dephosphorylating two key tyrosine-phosphorylated
proteins, thereby antagonizing the interaction of integrins
with the extracellular matrix and integrin-triggered signal-
ing pathways [65]. The dephosphorylating function of
PTEN is also necessary in the lipid signal transduction
PI3K pathway [53]. Therefore, PTEN acts as a unique
tumor suppressor by inhibiting lipid phosphatase and pro-
tein tyrosine phosphatase activity, thus negatively regulat-
ing cell proliferation and invasion. Our results are in
accordance with this scenario because we report that over-
expression of miR-21 post-transcriptionally downregulates
the expression of PTEN, inhibits cell proliferation and
promotes survival of SiHa and HeLa cells, which are hu-
man cervical cancer cells transformed with HPV16 and
HPV18, respectively. The principal novel contribution of
our data is to demonstrate that PTEN gene expression is
regulated by miR-21 and this regulation occurs mainly
through MRE21-2 within the PTEN 3′-UTR in cervical
cancer cells. This evidence strongly supports the notion of
a regulatory genetic network between miR-21 and PTEN
in cervical cancer cells.
During autophagy, acidic autophagic vacuoles, also
called autophagolysosomes, are formed as a result of fu-
sion of autophagosomes with lysosomes [66]. These are
a characteristic feature of cells engaged in autophagy.
Formation of autophagolysosomes can be detected by
fluorescence microscopy after staining with the lysomo-
tropic agent acridine orange. Staining of untreated cells
with acridine orange, a weak base generates green fluor-
escence of the cytoplasmic and nuclear components. In
larger acidic compartments such as autophagolysosomes,
the protonated form of acridine orange accumulates and
generates red fluorescence, when can be observed by
fluorescence microscopy (Fig. 5c). We analyzed the ef-
fect of silencing miR-21 on autophagy and early apop-
tosis by looking at formation of autophagolysosomes
with fluorescence microscopy after staining with acridine
orange and propidium iodide (Fig. 6). The results of
both the fluorescence microscopy and western blot as-
says indicate that silencing of miR-21 leads to increased
PTEN gene expression and are associated with autoph-
agy and early apoptosis processes. These mechanisms of
programmed cell death have been described previously
in renal tubular epithelial cells, and play an important
role in cell survival in response to stress [67].
We demonstrated that the processes of autophagy and
apoptosis occur in response to silencing of miR-21 and
are required for adaptation to conditions of stress in
cervical cancer cells. Thus, the induction of autophagy
during silencing of miR-21 in cervical cancer cells may
provide for an appropriate environment to maintain cellu-
lar homeostasis before reaching the threshold for
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apoptosis. Therefore, this evidence supports and
strengthens the concept of a regulatory genetic network
involving miR-21 in a positive feedback loop and down-
regulation of PTEN in human cervical cancer cells.
The ability to selectively silence mammalian gene ex-
pression using siRNAs offers new and exciting perspec-
tives in the field of mammalian cell biology and
pathology. However, it cannot be assumed that all genes
will be equally susceptible to the siRNA mechanism.
SiRNAs have been shown to knock down a large number
of genes expressed in mammalian cells and siRNA tech-
nology has been used to characterize mammalian gene
function [68–70]. An application of the siRNAs with
great potential is in specific gene therapy against cancer.
SiRNAs mimic endogenous microRNAs, which can ef-
fectively inhibit the translation of target mRNAs by
binding the mRNA 3′-UTR. This process is dependent
upon mRNA accessibility and, within the target mRNA
molecule, accessibility of the short internal nucleotide
sequences that are homologous to the siRNA transcripts.
Therefore, various factors can influence the susceptibility
of a given mRNA transcript to siRNA-mediated degrad-
ation. These include mRNA secondary structures and
proteins which package mRNA for translocation within
the cell. Other protein-mRNA interactions are also rele-
vant which direct a given mRNA to a specific sub-
cellular locus, and those mRNAs which can be bound by
the proteins they encode.
In summary, the findings of our investigation demon-
strate that siRNAs against miR-21 can produce a specific
decrease of miR-21 mRNA expression and reestablish
PTEN gene and protein expression, as well as lead to
growth suppression and induction of cell death by au-
tophagy and apoptosis. Thus, the biological effects of
miR-21 in cervical cancer cells can be explained, at least
in part, by miR-21’s regulation of the PTEN pathway.
The main novel contribution of our data is to demon-
strate that in cervical cancer, PTEN gene expression is
regulated by miR-21 and this regulation is mediated
mainly through the MRE21-2 recognition sequence
within PTEN’s 3′-UTR. We also demonstrate that silen-
cing miR-21 induces the death of cervical cancer cells.
This evidence strongly supports the existence and rele-
vance of a regulatory genetic network between miR-21
and PTEN in cervical cancer cells.
Conclusions
The findings and implications of this study are as fol-
lows: i) The administration of siRNAs expressed in plas-
mids specific to microRNA miR-21 induces the silencing
of miR-21 in human cervical cancer cells transformed by
HPV16. ii) The silencing of miR-21 induces reestablish-
ment of PTEN gene and protein expression. iii) The re-
establishment of PTEN may explain the biological
effects of silencing miR-21, which include induction of
cell death by autophagy and apoptosis in cervical cancer
cells. iv) The silencing of miR-21 expression by siRNAs
and its effects upon PTEN does not exclude other po-
tential molecular pathways in cervical carcinogenesis
that may be influenced by the silencing of miR-21, and
there exist excellent opportunities to identify new thera-
peutic molecular targets. Our findings suggest that a
therapeutic strategy employing siRNAs could effectively
inhibit the growth of virus-related cancers. The clinical
relevance of silencing miR-21 expression with siRNAs
will be better appreciated once they are applied in clin-
ical trial protocols. This goal will require selection of ad-
equate cloning vectors for siRNAs, development of
molecular vehicles to administer siRNAs at the tumor
site, and design of treatment schemes such as chemo-
therapy, radiotherapy or immunotherapy treatment to be
used in combination with siRNAs. Our results indicate
that siRNAs have a great potential in the treatment of
human malignancies such as cervical cancer. There is no
doubt that the siRNA technology platform is a realistic
gene therapy strategy against the development of
cervical cancer. The challenge is now to develop efficient
strategies for the application of this technology in
clinical trials.
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